DNA
What one share of Ginkgo Bioworks Holdings holds
Biological Products, (No Diagnostic Substances)
Our mission is to make biology easier to engineer. That has never changed. Every choice we’ve made with respect to our business model, our platform, our people, and our culture is grounded in whether it will advance our mission.
Ginkgo Bioworks Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.26 |
|---|---|
| Profit | −$4.96 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$2.98 |
| Cash and investments | $1.33 |
| Book value | $6.60 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $1.89 | −$4.00 | $0.77 | −$2.33 | — | $17.47 |
| 2020 | $2.41 | −$3.97 | $1.81 | −$6.08 | — | $14.32 |
| 2021 | $9.23 | −$55.60 | $1.66 | −$9.13 | — | $37.37 |
| 2022 | $11.38 | −$50.15 | $1.24 | −$7.25 | — | $36.71 |
| 2023 | $5.17 | −$18.37 | $0.84 | −$6.92 | — | $21.93 |
| 2024 | $4.38 | −$10.54 | $1.21 | −$7.36 | — | $13.17 |
| 2025 | $3.07 | −$5.64 | $0.14 | −$3.22 | — | $8.74 |